About HEC

Close 80 Billion

Total assets

2

Listed Companies

20000 People

+

Existing staff

50000

Laboratory

1700 People

+

R & D team

3500 Item

+

Patents

Company Profile

HEC is a high-tech large-scale joint-stock enterprise full of hope, focusing on industry and building a century-old foundation.

HEC is a high-tech large-scale joint-stock enterprise full of hope, focusing on industry and building a century-old foundation. It has more than 20,000 employees; it is mainly engaged in three major industries: "electronic new materials", "biomedicine" and "health and wellness". Now there are seven bases, located in Dongguan in Guangdong, Shaoguan in Guangdong, Yichang in Hubei, Dongyang in Zhejiang, Ulanchap in Inner Mongolia, Guiqing, and Nyingchi in Tibet. It has two listed companies: HEC (600676.SH) and HEC Pharmaceutical (01558.HK).

Learn more →

Development Path

The company was established in 1997

Learn more →

Enterprise Honor

More than 3,500 patents have been applied, including more than 1,500 foreign patents

 
Learn more →

Social Responsibility

HEC Group has made accumulative donations worth over 200 million yuan to the field of social welfare and charity

 
Learn more →

Staff Corner

More than 20,000 employees

 
Learn more →
  • HEC Technology

    HEC Technology

  • HEC Pharmaceutical

    HEC Pharmaceutical

  • HEC Health

    HEC Health

HEC Technology

HEC Technology - The new electronic materials sector has formed the A-share listed company HEC (600673.SH), and has built a large-scale industrialization base with Shaoguan in Guangdong as the mainstay, and Yichang in Hubei, Dongyang in Zhejiang, Ulanchap in Inner Mongolia, and Zunyi in Guizhou for coordinated development. The new energy research institute with strong research and development strength has established a post-doctoral research station and is a national enterprise technology center.

  • HEC Technology
  • HEC Technology
Learn more →

HEC Pharmaceutical

HEC Pharmaceutical - HEC Biopharmaceutical segment includes three major businesses: HEC Research, HEC Pharmaceutical (01558.HK) and fermented APIs. Among them, the R&D and pharmaceutical business for foreign markets constitute HEC Research; the domestic preparation business is integrated into HEC Pharmaceutical, which has been listed on the Hong Kong stock market; fermented APIs mainly include macrolide APIs and other businesses.

  • 东阳光药
  • 东阳光药
Learn more →

HEC Health

HEC Health - HEC Health has a research institute with more than 200 high-end R&D talents, and has built an industrialization base mainly in Yichang, Hubei, supplemented by Shaoguan, Guangdong and Nyingchi, Tibet. In the future, the research and development and production base of Cordyceps sinensis deep processing products will be built in Zhuhai Hengqin and Dongyang, Zhejiang. Adhering to the concepts of safety, health, ecology and high technology, HEC will build a large-scale health industry dominated by Cordyceps sinensis, and continue to develop and innovate ecologically bred Cordyceps sinensis and its deep-processed products, health food, health care products, cosmetics and other large-scale health products cluster.

  • 东阳光健
  • 东阳光健
Learn more →

R & D Center

In 2005, HEC established the General Research Institute, which consists of three branches: the Pharmaceutical Research Institute, the Great Health Research Institute and the New Energy Research Institute. Through 17 years of unremitting efforts, it has possessed continuous and systematic research and development capabilities. The research and development concept is occidentalized, the scientific research talents are globalized, and the research and development and testing equipment are first-class.

Learn more →

R & D Team

The institute has more than 20 foreign and returnee experts, more than 100 doctors, more than 1,000 masters, more than 1,700 R&D personnel, and has first-class medicinal chemistry capabilities, thus forming a unique R&D model of "domestic elite-led, returnee expert guidance, overseas consultant guidance”. 

Learn more →

R & D Results

The institute has applied for more than 3,500 patents, and its foreign patents are more than 1,500; the total number of pharmaceutical patents, compound patents, compound PCT patents, patent application growth rate and patent quality applied by HEC drugs each year rank in the forefront of China.

Learn more →
Seven Bases Business Distribution
  • Foreign markets account for nearly15%

    Coordinated development of five platforms (HEC technology sales platform, HEC pharmaceutical sales platform, HEC health sales platform, API sales department, overseas sales department)

    HEC Overseas Sales Department has established 15 overseas branches in Japan, the United States, Germany, Australia, the United Kingdom, South Korea, Indonesia, France, India and other developed countries.

    More than 4,000 full-time sales staff

    HEC Trends

    Create a tens of billions of Cordyceps sinensis industry! Cordyceps sinensis deep processing and transformation base settled in Hengqin

    On November 10, the Executive Committee of the Hengqin Guangdong-Macao Deep Cooperation Zone (hereinafter referred to as the “Cooperation Zone”) signed a framework cooperation agreement with HEC Group. According to the agreement, the deep processing and transformation base of Cordyceps sinensis has settled in Hengqin. It is expected that in five years, the output value will reach at least 10 billion.

    2022-11-10

    Incredible! HEC Pharma won 5.6 billion major varieties

    So far, HEC Pharma has 4 insulin products approved for marketing, including human insulin injection, insulin glargine injection, insulin aspart injection, and insulin aspart 30 injection. In addition, the marketing application of protamine-human insulin mixed injection (30R) is under review and is expected to be approved for marketing in 2023.

    2022-11-07

    Chinese pharmaceutical enterprise successfully challenged the original drug patent in the United States for the first time

    On October 19, HEC Group announced on the WeChat official account that the ’405 patent was officially declared invalid by the American court on October 18, and Sunshine Lake Pharma Co., Ltd. (hereinafter referred to as Sunshine Lake Pharma) has officially been approved to market its first generic drug Fingolimod capsules in the United States.

    2022-10-20